ECSP21031200A - USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY - Google Patents

USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY

Info

Publication number
ECSP21031200A
ECSP21031200A ECSENADI202131200A ECDI202131200A ECSP21031200A EC SP21031200 A ECSP21031200 A EC SP21031200A EC SENADI202131200 A ECSENADI202131200 A EC SENADI202131200A EC DI202131200 A ECDI202131200 A EC DI202131200A EC SP21031200 A ECSP21031200 A EC SP21031200A
Authority
EC
Ecuador
Prior art keywords
narcolepsy
treatment
reboxetin
reboxetine
cataplexy
Prior art date
Application number
ECSENADI202131200A
Other languages
Spanish (es)
Inventor
Tabuteau Herriot
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of ECSP21031200A publication Critical patent/ECSP21031200A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La patente consiste en métodos para el tratamiento de narcolepsia con cataplexia, que comprenden la administración de reboxetina a un ser humano que lo necesita. La reboxetina también se puede usar en la elaboración de un medicamento para el tratamiento de la narcolepsia con cataplexia. También se describen en el presente documento kits que comprenden una composición farmacéutica que comprende reboxetina e instrucciones para usar la composición farmacéutica para tratar la narcolepsia con cataplexia en un ser humano.The patent consists of methods for the treatment of narcolepsy with cataplexy, which comprise the administration of reboxetine to a human being in need. Reboxetine can also be used in the manufacture of a drug for the treatment of narcolepsy with cataplexy. Also described herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions for using the pharmaceutical composition to treat cataplexy narcolepsy in a human.

ECSENADI202131200A 2018-10-15 2021-04-30 USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY ECSP21031200A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862745956P 2018-10-15 2018-10-15
PCT/US2019/056134 WO2020081461A1 (en) 2018-10-15 2019-10-14 Use of reboxetine to treat narcolepsy

Publications (1)

Publication Number Publication Date
ECSP21031200A true ECSP21031200A (en) 2021-05-31

Family

ID=70284075

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202131200A ECSP21031200A (en) 2018-10-15 2021-04-30 USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY

Country Status (16)

Country Link
EP (1) EP3866768A4 (en)
JP (1) JP2022504975A (en)
KR (1) KR20210071046A (en)
CN (1) CN112888430A (en)
AU (2) AU2019361915A1 (en)
BR (1) BR112021007019A2 (en)
CA (1) CA3115983A1 (en)
CL (1) CL2021000924A1 (en)
CO (1) CO2021004681A2 (en)
CR (1) CR20210514A (en)
EC (1) ECSP21031200A (en)
IL (1) IL282311A (en)
MX (1) MX2021004207A (en)
PE (1) PE20211199A1 (en)
SG (1) SG11202103588WA (en)
WO (1) WO2020081461A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
KR20230055668A (en) * 2021-10-19 2023-04-26 단국대학교 천안캠퍼스 산학협력단 Composition for preventing or treating sarcopenia comprising reboxetine as an active ingredient

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485746B1 (en) * 2000-08-25 2002-11-26 Neurocrine Biosciences, Inc. Controlled-release sedative-hypnotic compositions and methods related thereto
KR20070029740A (en) * 2004-06-09 2007-03-14 화이자 인코포레이티드 Use of reboxetine for the treatment of pain
HRP20221018T1 (en) * 2013-03-13 2023-01-06 Jazz Pharmaceuticals Ireland Limited Treatment of cataplexy

Also Published As

Publication number Publication date
CR20210514A (en) 2021-11-12
CL2021000924A1 (en) 2021-09-03
SG11202103588WA (en) 2021-05-28
CO2021004681A2 (en) 2021-06-21
CN112888430A (en) 2021-06-01
PE20211199A1 (en) 2021-07-01
MX2021004207A (en) 2021-08-11
BR112021007019A2 (en) 2021-07-13
JP2022504975A (en) 2022-01-13
EP3866768A1 (en) 2021-08-25
WO2020081461A1 (en) 2020-04-23
AU2019361915A1 (en) 2021-05-13
KR20210071046A (en) 2021-06-15
AU2023200917A1 (en) 2023-03-23
EP3866768A4 (en) 2022-01-05
CA3115983A1 (en) 2020-04-23
IL282311A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
ECSP21031200A (en) USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY
CL2023001949A1 (en) Antibodies targeting HIV gp120 and methods of use (divisional patent application no. 3422-2020)
CL2017002996A1 (en) Tetra-substituted alkene compounds and their use
CR20190350A (en) ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFß1 INHIBITORS AND USE THEREOF
CO2022010330A2 (en) Gamma-Hydroxybutyrate (GHB) Dosage
BR112016027773A2 (en) cell penetrating peptide, polynucleotide, recombinant botulinum toxin penetrating cell protein, recombinant expression vector, bacterium, pharmaceutical composition, cosmetic composition and method for producing a recombinant botulinum toxin cell penetrating protein
GT201700246A (en) METHODS AND KITS TO TREAT DEPRESSION
CL2016002516A1 (en) "Substituted spirocycle derived compounds, atx inhibitors; pharmaceutical composition comprising them; and its use in the treatment of cancer, inflammations, neuropathic pain, fibrotic diseases, thrombosis, among others ”. pct
BR112018008684A2 (en) injectable botulinum toxin formulations and processes of long-term use of the therapeutic or cosmetic effect
CO2020009670A2 (en) Compositions comprising the co-selected microbiota and methods for their use
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
BR112018076639A2 (en) combination chemotherapies
CO2021015793A2 (en) Methods of treating or preventing asthma by administering an il-33 antagonist
BR112017006113A8 (en) Auristatin uses, pharmaceutical compositions, dosage forms for cancer treatment and kits.
CY1122882T1 (en) 3-(CARBOXYETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES
CO2022014499A2 (en) nlrp3 modulators
MX2020004513A (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same.
CL2022003426A1 (en) Levilimab Aqueous Pharmaceutical Composition and Its Use
CL2022001079A1 (en) Methods and compositions for the treatment of rett syndrome
CL2021003442A1 (en) Pharmaceutical composition comprising idelalisib and defactinib; and methods for treating cancer.
AR122344A1 (en) USE OF REBOXETINE TO TREAT NERVOUS SYSTEM DISORDERS
CL2021000858A1 (en) Derivatives of 4-pyrazin-2-ylmethyl-morpholine and their use as a medicine
CO2022007507A2 (en) Use of reboxetine to treat disorders of the nervous system
AR103636A1 (en) METHODS OF TREATMENT OF POSTERPEPTIC NEURALGY WITH A TOPICAL FORMULATION OF AN ESPIRO-OXINDOL COMPOUND
CL2022001476A1 (en) Use of reboxetine to treat disorders of the nervous system